Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by NEOS Investment Management LLC

NEOS Investment Management LLC decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.1% in the 4th quarter, Holdings Channel reports. The fund owned 61,503 shares of the biotechnology company’s stock after selling 3,990 shares during the period. NEOS Investment Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,156,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $38,000. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares during the last quarter. KBC Group NV increased its position in shares of Arrowhead Pharmaceuticals by 45.9% during the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 1,644 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter worth about $149,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $190,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In other news, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.83, for a total value of $538,721.61. Following the completion of the sale, the chief financial officer now owns 473,433 shares in the company, valued at $9,388,176.39. This represents a 5.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. The trade was a 3.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 286,317 shares of company stock valued at $5,049,735 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $13.82 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $13.66 and a 12-month high of $30.41. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. The business has a 50 day simple moving average of $18.13 and a 200 day simple moving average of $19.61.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. B. Riley reissued a “buy” rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.